Neurol. praxi. 2015;16(3):163-166

Clinical and genetic heterogenity of dopa-responsive dystonia

MUDr. Ján Necpál
Neurologické oddelenie, Nemocnica Zvolen, a. s., Zvolen

Dopa-responsive dystonia, one of the dystonia-plus syndromes, is a rare neurometabolic disorder caused by alteration of dopamine biosynthesis, mainly by mutation in GTP-cyclohydrolase I. gene. It is characterised by early onset dystonic gait with frequent generalisation, parkinsonism, diurnal fluctuation of the symptoms and excellent long-term levodopa-responsiveness without chronic motor complications of levodopa therapy. The disorder is genetically heterogeneous and therefore clinically often atypical. As an example it is presented a case report of the patient and her daughter detected with a new mutation in GTP-cyclohydrolase I. gene.

Keywords: dopa-responsive dystonia, dystonia, genetics, DRD-plus, case report

Published: June 26, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Necpál J. Clinical and genetic heterogenity of dopa-responsive dystonia. Neurol. praxi. 2015;16(3):163-166.

Video

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bonafe L, Thony B, Penzien JM, Czarnecki B, Blau N. Mutations in sepapterin reductase gene cause a novel tetrahydrybiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninaemia. Am J Hum Genet. 2001; 69: 269-277. Go to original source... Go to PubMed...
    2. Bräutigam C, Steenbergen-Spanjers GC, Hoffman GF, Dionisi-Vici C, van den Heuvel LPWJ, Smeitink JAM, Wevers RA. Biochemical and molecular genetic characteristics of the severe form of tyrosine hydroxylase deficiency. Clin Chem. 1999; 45: 2073-2078. Go to original source...
    3. Donaldson IM, Marsden CD, Schneider SA, Bhatia KP. Marsden's book of movement disorders. New York: Oxford University Press Inc.; 2012: 1552. Go to original source...
    4. Furukawa Y, Guttman M, Kish S. Dopa-Responsive Dystonia. In: Frucht SJ, Fahn S. Movement Disorder Emergencies. Diagnosis and Treatment. Totowa, NJ: Humana Press Inc., 2005: 209-231. Go to original source...
    5. Gasser T, Asmus F, Kamm C. Dystonia-plus syndromes. In: Warner TT, Bressman SB. Clinical Diagnosis and Management of Dystonia. Informa UK Ltd: 2007: 121-130. Go to original source...
    6. Grimes DA, Barclay CL, Duff J, Furukawa Y, Lang AE. Phenocopies in a large GCH1 mutation positive family with dopa responsive dystonia: confusing the Picture? J Neurol Neurosurg Psychiatry. 2002; 72: 801-804. Go to original source... Go to PubMed...
    7. Hagenah J, Saunders-Pullman R, Hedrich K, Kabakci K, Haberman K, Wiegers K, Mohrmann K, Lohnau T, Ryamond D, Vieregge P, Nygaard T, Ozelius LJ, Bressman SB, Klein C. High mutation rate in dopa-responsive dystonia: Detection with comprehensive GCH1 screening. Neurology. 2005; 64: 908-911. Go to original source... Go to PubMed...
    8. Jeon BS. Dopa-Responsive Dystonia: A syndrome of selective nigrostriatal dopaminergic deficiency. JKMS. 1997; 12: 269-279. Go to original source... Go to PubMed...
    9. Kamm C. Dopa-responsive dystonia [online]. November 2013. Available from: <http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=255>. Accessed August 25, 2014.
    10. Lee WW, Jeon BS. Clinical Spectrum of Dopa-Responsive Dystonia and Related Disorders. Curr Neurol Neurosci Rep. 2014;14:461. Go to original source... Go to PubMed...
    11. Müller K, Hömberg V, Lenard HG. Motor control in childhood onset dopa-responsive dystonia (Segawa syndrome). Neuropediatrics. 1989; 20: 185-191. Go to original source... Go to PubMed...
    12. Nygaard TG, Marsden CD, Duvoisin RC. Dopa-responsive dystonia. Adv Neurol. 1988; 50: 337-384.
    13. Nygaard TG, Snow BJ, Fahn S, Calne DB. Dopa-responsive dystonia: clinical characteristics and definition. In: Segawa M, ed. Hereditary progressive dystonia with marked diurnal fluctuation. New York, NY: Parthenon, 1993: 21-35.
    14. Nygaard TG, Trugman JM, de Yebenes JG, Fahn S. Dopa-responsive dystonia: the spectrum of clinical manifestations in a large North American family. 1990; 40: 66-69. Go to original source... Go to PubMed...
    15. Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H. Hereditary progressive dystonia with marked diaurnal variation. Adv Neurol. 1976; 14: 215-233.
    16. Segawa M, Nomura Y. Hereditary progressive dystonia with marked diurnal fluctuation. In: Segawa M, ed. Hereditary progressive dystonia with marked diurnal fluctuation. New York, NY: Parthenon, 1993: 3-19. Go to original source...
    17. Segawa M, Ohmi K, Itoh S, Aoyama M, Hayakawa H. Childhood basal ganglia disease with marked response to L-Dopa, "Hereditary progressive basal ganglia disease with marked diurnal fluctuaction". Shinryo. 1972; 24: 667-672.
    18. The Human Gene Mutation Database [online]. Available from: <http://www.hgmd.cf.ac.uk./ac/gene.php?gene=GCH1>.
    19. Zirn B, Steinberger D, Troidl C, Brockmann K, von der Hagen M, Feiner C, Henke L, Müller U. Frequency of GCH1 deletions in Dopa-responsive dystonia. J Neurol Neurosurg Psychiatry. 2008; 79: 183-186. Go to original source... Go to PubMed...
    20. Wider C, Melquist S, Hauf M, Solida A, Cobb SA, Kachergus JM, Gass J, Coon KD, Baker M, Cannon A, Stephan DA, Schorderet DF, Ghika J, Burkhard PR, Kapatos G, Hutton M, Farrer MJ, Wszolek ZK, Vingerhoets FJG. Study of a Swiss dopa-responsive dystonia family with a deletion in GCH1: redefining DYT14 as DYT5. Neurology. 2008; 70: 1377-1383. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.